Form D · Other Health Care

Carbylan Therapeutics, Inc.

Palo Alto, CA · CIK 0001348911

Offering snapshot reported Mar 5, 2015 · SEC filing

Reported sold
$4M
Offering amount: $4M
Investors reported
4
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Feb 19, 2015
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 5, 2015Initial$4,000,000No comparison4SEC filing
Oct 14, 2014Initial$5,000,000No comparison4SEC filing
Jan 3, 2013Initial$5,999,999No comparison4SEC filing
Dec 29, 2005PaperNot reportedNo comparisonNot reportedSEC filing
Dec 29, 2005PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Debt, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-235286

Source: Form D, filed Mar 5, 2015. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Steven L. Basta Director
Albert Cha Director
David Clapper Director
George Daniloff Director, Executive
Roxanne Dubois Executive
Chris Ehrlich Director
David M. Gravett Executive
Keith A. Katkin Director
Hayley Lewis Executive
Marcee M. Maroney Executive
Guy P. Nohra Director
David M. Renzi Director, Executive
Timothy L. Trapp Executive
Edward W. Unkart Director
Mark Weeks Executive
T. Michael White Executive
Reza Zadno Director

Issuer details

Industry: Other Health Care (See others in industry)

Address:
3181 Porter Drive
Palo Alto, CA, 94304